Celularity Inc. (NASDAQ:CELU – Get Rating) saw a significant decline in short interest during the month of August. As of August 31st, there was short interest totalling 1,800,000 shares, a decline of 31.3% from the August 15th total of 2,620,000 shares. Approximately 5.0% of the company’s shares are sold short. Based on an average trading volume of 667,800 shares, the days-to-cover ratio is currently 2.7 days.
Institutional Trading of Celularity
Large investors have recently modified their holdings of the company. Legal & General Group Plc bought a new position in Celularity in the second quarter worth approximately $29,000. Occudo Quantitative Strategies LP bought a new position in Celularity in the second quarter worth approximately $125,000. State Street Corp bought a new position in Celularity in the second quarter worth approximately $697,000. Cubist Systematic Strategies LLC acquired a new position in shares of Celularity during the second quarter worth $48,000. Finally, UBS Asset Management Americas Inc. acquired a new position in shares of Celularity during the second quarter worth $99,000. Hedge funds and other institutional investors own 22.35% of the company’s stock.
Celularity Stock Performance
Shares of NASDAQ CELU opened at $2.15 on Friday. The firm has a market capitalization of $297.37 million, a price-to-earnings ratio of 10.24 and a beta of 0.20. The stock has a 50 day moving average price of $3.10 and a 200 day moving average price of $6.14. Celularity has a 52-week low of $1.97 and a 52-week high of $13.19.
Wall Street Analysts Forecast Growth
Celularity Company Profile
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.
- Get a free copy of the StockNews.com research report on Celularity (CELU)
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It’s a Down Week
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.